文献速递创伤与烧伤呼吸衰竭与机械通气重症综合管理与镇静镇痛

严重创伤性脑损伤不再是大面积肋骨骨折手术固定的禁忌证?一项倾向匹配分析

Is severe traumatic brain injury no longer a contraindication for surgical stabilization of rib fractures in patients with multiple rib fractures? A propensity-matched analysis.
PubMed 文献 · J Trauma Acute Care Surg · 2023-03-11
一句话结论在合并创伤性脑损伤的多发肋骨骨折患者中,肋骨骨折手术固定与院内死亡率降低相关,但住院和ICU时间延长;作者认为应考虑手术固定。

该研究利用美国外科医师学会创伤质量改进项目2016-2019年数据,回顾性分析合并创伤性脑损伤(TBI)与多发肋骨骨折的患者,经倾向评分匹配后比较肋骨骨折手术固定(SSRF)与非手术管理的结局。主要终点为死亡率,SSRF组死亡率为5.4%,非手术组为14.5%(p<0.001);SSRF组住院时间更长(15天 vs 9天)、ICU时间更长(12天 vs 8天)、机械通气天数更多(7天 vs 4天)。亚组分析中,轻中度TBI(GCS>8)和重度TBI(GCS≤8)患者SSRF均与死亡率降低相关。作者认为,对合并TBI的多发肋骨骨折患者应考虑SSRF。

要点

  • 在合并TBI的多发肋骨骨折患者中,SSRF与院内死亡率降低相关(5.4% vs 14.5%,p<0.001)。
  • SSRF组住院时间(15天 vs 9天)、ICU时间(12天 vs 8天)和机械通气天数(7天 vs 4天)均较非手术组长,p均<0.001。
  • 轻中度TBI(GCS>8)亚组:SSRF与死亡率降低相关(5.0% vs 9.9%,p=0.006),住院、ICU和通气时间均延长(p<0.001)。
  • 重度TBI(GCS≤8)亚组:SSRF与死亡率降低相关(6.2% vs 18%,p<0.001),住院时间(20天 vs 14天,p=0.001)和ICU时间(16天 vs 13天,p=0.004)延长。
  • 作者认为,对合并TBI的多发肋骨骨折患者应考虑SSRF;证据等级为治疗/管理Level III。

适用人群与场景

  • 合并创伤性脑损伤(TBI)与多发肋骨骨折、纳入美国外科医师学会创伤质量改进项目(2016-2019年)的患者。
  • 亚组分析按GCS评分分层:轻中度TBI(GCS>8)和重度TBI(GCS≤8)。

诊断标准与关键阈值

  • TBI严重程度分层依据GCS评分:轻中度TBI为GCS>8,重度TBI为GCS≤8。

研究设计与关键结果

  • 研究类型:基于美国外科医师学会创伤质量改进项目2016-2019年的回顾性分析,经倾向评分匹配比较SSRF与非手术管理。
  • 共纳入36,088例患者,其中879例(2.4%)接受SSRF。
  • 主要终点:SSRF组院内死亡率5.4%,非手术组14.5%(p<0.001)。
  • 次要终点:SSRF组住院时间15天 vs 非手术组9天(p<0.001),ICU时间12天 vs 8天(p<0.001),机械通气天数7天 vs 4天(p<0.001)。
  • 轻中度TBI亚组(GCS>8):SSRF组死亡率5.0% vs 非手术组9.9%(p=0.006),住院时间13天 vs 9天(p<0.001),ICU时间10天 vs 7天(p<0.001),通气天数5天 vs 2天(p<0.001)。
  • 重度TBI亚组(GCS≤8):SSRF组死亡率6.2% vs 非手术组18%(p<0.001),住院时间20天 vs 14天(p=0.001),ICU时间16天 vs 13天(p=0.004)。

证据类型、等级与局限

  • 证据类型:回顾性分析(倾向评分匹配),证据等级为治疗/管理Level III。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,对合并TBI与多发肋骨骨折的患者应考虑SSRF;该结论来自回顾性倾向匹配分析,证据等级为Level III。
  • SSRF与死亡率降低相关,但住院时间、ICU时间和机械通气天数均延长,临床决策时需结合这些结局综合评估。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Traumatic brain injury (TBI) is often considered a contraindication to surgical stabilization of rib fractures (SSRF). In this study, we hypothesized that, compared with nonoperative management, SSRF is associated with improved outcomes in TBI patients.

METHODS: Using the American College of Surgeons Trauma Quality Improvement Program 2016-2019, we performed a retrospective analysis of patients with concurrent TBI and multiple rib fractures. Following propensity score matching, we compared patients who underwent SSRF with those who were managed nonoperatively. Our primary outcome was mortality. Secondary outcomes included ventilator-associated pneumonia, hospital and intensive care unit (ICU) length of stay (LOS), ventilator days, tracheostomy rate, and hospital discharge disposition. In a subgroup analysis, we stratified patients into mild and moderate TBI (GCS score >8) and severe TBI (GCS score ≤8).

RESULTS: Of 36,088 patients included in this study, 879 (2.4%) underwent SSRF. After propensity-score matching, compared with nonoperative management, SSRF was associated with decreased mortality (5.4% vs. 14.5%, p < 0.001), increased hospital LOS (15 days vs. 9 days, p < 0.001), increased ICU LOS (12 days vs. 8 days, p < 0.001), and increased ventilator days (7 days vs. 4 days, p < 0.001). In the subgroup analyses, in mild and moderate TBI, SSRF was associated with decreased in-hospital mortality (5.0% vs. 9.9%, p = 0.006), increased hospital LOS (13 days vs. 9 days, p < 0.001), ICU LOS (10 days vs. 7 days, p < 0.001), and ventilator days (5 days vs. 2 days, p < 0.001). In patients with severe TBI, SSRF was associated with decreased mortality (6.2% vs. 18%, p < 0.001), increased hospital LOS (20 days vs. 14 days, p = 0.001), and increased ICU LOS (16 days vs. 13 days, p = 0.004).

CONCLUSION: In patients with TBI and multiple rib fractures, SSRF is associated with a significant decrease in in-hospital mortality and with longer hospital and ICU LOSs. These findings suggest that SSRF should be considered in patients with TBI and multiple rib fractures.

LEVEL OF EVIDENCE: Therapeutic/Care Management; Level III.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Lagazzi E, de Roulet A, Proaño-Zamudio JA, et al. Is severe traumatic brain injury no longer a contraindication for surgical stabilization of rib fractures in patients with multiple rib fractures? A propensity-matched analysis. J Trauma Acute Care Surg. 2023. PMID: 37079864. doi:10.1097/TA.0000000000003954

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。